Genelux (GNLX) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Genelux (GNLX) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 57.7% versus a loss of 67.6%. Genelux is the larger company by market cap ($109.5 million vs $103.6 million), about 1.1 times the size, while Tonix Pharmaceuticals is growing revenue faster (+29.8% vs +0.0%). Tonix Pharmaceuticals converts more of its revenue into profit, with a net margin of -946.2% versus -401812.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | TNXP |
|---|---|---|
| Share price | $2.42 | $6.04 |
| Market cap | $109.49M | $103.59M |
| 1-day change | -2.42% | -5.92% |
| YTD return | -44.50% | -61.33% |
| 1-year return | -57.69% | -67.56% |
| 5-year return | — | -100.00% |
| EPS (TTM) | $-0.86 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.00K | $13.11M |
| Revenue growth (YoY) | 0.00% | +29.85% |
| Net income (latest FY) | $-32.15M | $-124.02M |
| Gross margin | — | 49.34% |
| Operating margin | -415175.00% | -959.05% |
| Net margin | -401812.50% | -946.22% |
| 52-week high | $8.54 | $20.58 |
| 52-week low | $2.29 | $6.01 |
| Distance from 52-week high | -71.65% | -70.65% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +678.10% | +636.75% |
| Average volume | 288.93K | 607.68K |
| Shares outstanding | 45.25M | 17.15M |
| Employees | 25 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Tonix Pharmaceuticals is more profitable, keeping -946.2 cents of every revenue dollar as net income versus -401812.5 cents for Genelux.
- Tonix Pharmaceuticals grew revenue faster in its latest fiscal year (+29.85% vs 0.00%).
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
GNLX vs TNXP FAQ
Which is bigger, Genelux or Tonix Pharmaceuticals?
Genelux (GNLX) is larger, with a market capitalization of $109.49M compared with $103.59M for Tonix Pharmaceuticals (TNXP).
Which stock has performed better over the past year, GNLX or TNXP?
GNLX returned -57.69% over the past 12 months, compared with -67.56% for TNXP (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and Tonix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.